<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the ğŸ”— symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, iv doior.102020.t of en, Dis  et i, and e.g. vieord.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### [Press Release (Oct 16)](/page/updates/#press.release)
- [IFN Lambda EigerBioPharmaceuticals](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Eiger20201017.pdf)

### [Clinical Trials (Oct 15)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-15)

### Database Entries(Oct 13)
Olaleye OA, Kaur M, and Onyenaka CC. [â€œAmbroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Proteinâ€™s Receptor Binding Domain and Recombinant Human ACE2.â€](/search/?article=Olaleye20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.13.295691](https://doi.org/10.1101/2020.09.13.295691). \[[PubMed32995775](https://www.ncbi.nlm.nih.gov/pubmed/32995775/)\] \[[PMC7523101](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523101/)\]

### Database Entries(Oct 13)
Kaptein SJF, Jacobs S, et int., and Delang L. [â€œFavipiravir at high doses has potent antiviral activity in  etint. an aer  e noodesn o comoa SARS-CoV-2âˆ’infected hamsters, whereas hydroxychloroquine lacks activity.â€](/search/?article=Kaptein20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2014441117](https://doi.org/10.1073/pnas.2014441117). \[[PubMed33037151](https://www.ncbi.nlm.nih.gov/pubmed/33037151/)\]

### Database Entries(Oct 12)
Arabi YM, Asiri AY, et int., and Alothman A. [â€œInterferon Beta-1b and Lopinavirâ€“Ritonavir for Middle East Respiratory Syndrome.â€](/search/?article=Arabi20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2015294](https://doi.org/10.1056/nejmoa2015294). \[[PubMed33026741](https://www.ncbi.nlm.nih.gov/pubmed/33026741/)\]
### Database Entries(Oct 12)
Beigel JH, Tomashek KM, et int., and Lane HC. [â€œRemdesivir for the Treatment of Covid-19 â€” Final Report.â€](/search/?article=Beigel20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2007764](https://doi.org/10.1056/nejmoa2007764). \[[PubMed32445440](https://www.ncbi.nlm.nih.gov/pubmed/32445440/)\] \[[PMC7262788](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/)\]
### Database Entries(Oct 12)
Cho J, Lee YJ, et int., and Choi J. [â€œAntiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.â€](/search/?article=Cho20) _SREP_, 2020. [doi.org/10.1038/s41598-020-72879-7](https://doi.org/10.1038/s41598-020-72879-7). \[[PubMed33004837](https://www.ncbi.nlm.nih.gov/pubmed/33004837/)\] \[[PMC7530981](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530981/)\]
### Database Entries(Oct 12)
Gilmore K, Zhou Y, et int., and Seeberger PH. [â€œIn vitro efficacy of Artemisinin-based treatments against SARS-CoV-2[Newly added referencetes/#changelog)

Brunaugh AD, Seo H, et int., and Smyth HD. [â€œBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.â€](/search/?article=GilmoreBrunaugh20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.05.32663709.24.310490](https://doi.org/10.1101/2020.10.05.32663709.24.310490).

### [Preprints => Peer-Reviewed Publications (Oct lading ceestas.

### [oa 12)]/page/updates/#preprints.peer-reviewed.publications)

3 publishNewly added preprints were added.

### [Clinical Trials (Oct 09)](/page/updates/#clinical.trials)
[23 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-08)


### [New spike structures (Oct 08)](/page/spike-structures/#figure.11.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.spike.receptor.binding.domain.rbd.)
Figure 11. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) spike receptor binding domain (RBD).

### [New spike structures (Oct 08)](/page/spike-structures/#figure.12.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.trimeric.spike.)
Figure 12. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) trimeric spike.

### Webinar (Oct 07)
Monoclonal Antibodies for the Prevention and Treatment of COVID 19. [video](https://www.youtube.com/watch?v=YUj9jBlTCrY)

### [Press Release (Oct 07)](/page/press-release)
- [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202010071.pdf)
- [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202010072.pdf)

### Database entries(Oct 05)
Ansarin K, Tolouian R, et int., and Chapman KR. [â€œEffect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.â€](/search/?article=Ansarin20) _BioImpacts_, 2020. [doi.org/10.34172/bi.2020.27](https://doi.org/10.34172/bi.2020.27). \[[PubMed32983936](https://www.ncbi.nlm.nih.gov/pubmed/32983936/)\] \[[PMC7502909]\](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502909/)
### Database entries(Oct 05)
Wahl A, Gralinski L, et int., and Garcia JV. [â€œAcute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.â€](/search/?article=Wahl20) _Research square_, [2020. doi.org/10.21203/rs.3.rs-80404/v1](https://doi.org/10.21203/rs.3.rs-80404/v1). \[[PubMed32995766](https://www.ncbi.nlm.nih.gov/pubmed/32995766/)\] \[[PMC7523135](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523135/)\]
### Database entries(Oct 03)
Jones BE, Brown-Augsburger PL, et int., and Falconer E. [â€œLY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.â€](/search/?article=Jones20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.30.318972](https://doi.org/10.1101/2020.09.30.318972).
### Database entries(Oct 03)
Sagar S, Rathinavel AK, et int., and Radhakrishnan P. [â€œBromelain Iference (Sep 29)](/page/updates/#changelog)

Curreli F, Victor SMB, et int., and Debnath AK. [â€œStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibits SARS-CoV-2 Iinfection in VeroE6 Cellsvitro.â€](/search/?article=SagarCurreli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.16.297366](https://doi.org/10.1101/2020.09.16.297366). \[[PubMed32995771](https://www.ncbi.nlm.nih.gov/pubmed/32995771/)\] \[[PMC7523097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523097/)\]
### Database entries(Oct 03)
Watson A, Ferreira L, et int., and Stroud R. [â€œPeptide Antidotes to SARS-CoV-2 (COVID-19).â€](/search/?article=Watson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.06.238915](https://doi.org/10.1101/2020.08.06.238915).

### [Press Release (Oct 02)](/page/press-release)

[Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Synairgen20200930.pdf)

### [Press Release (Oct 02)](/page/press-release)

[Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20200930.pdf)

### [Press Release (Oct 02)](/page/press-release)

[Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20200930.pdf)

### [Clinical Trials (Oct 01)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the reg8.25.266437](https://doi.org/10.1101/2020.08.25.266437).

### [New clinical trials (Sep 28)](/page/updates/#new.clinical.trials.sep.28.)

14 clinical trials were added since September 24: [listry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-01)

### Database entries (Oct 01)
Proud PC, Tsitoura D, et int., and Carroll MW. [â€œProphylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.â€](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
### Database entries (Oct 01)
Son J, Huang S, et int., and Ding S. [â€œNitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.â€](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
### Database entries (Oct 01)
Fagre AC, Manhard J, et int., and Schountz T. [â€œA potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.â€](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
### Database entries (Oct 01)
Lin C, Li Y, et int., and Chen J. [â€œCeftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.â€](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
### Database entries (Oct 01)
Xiao T, Lu J, et int., and Chen B. [â€œA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.â€](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
### Database entries (Oct 01)
Zhang L, Cao L, et int., and Zhu F. [â€œA proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.â€](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### Database entries (Sep 29)
Brunaugh AD, Seo H, et int., and Smyth HD. [â€œBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.â€](/search/?article=Brunaugh20)Â _bioRxiv_,Â 2020.Â [doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
### Database entries (Sep 29)
Curreli F, Victor SMB, et int., and Debnath AK. [â€œStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.â€](/search/?article=Curreli20)Â _bioRxiv_,Â 2020.Â [doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
### Database entries (Sep 25)
new clinical trials](/clinical-trials/?fromDate=2020-09-24).

### [Published preprints (Sep 28)](/page/updates/#published.preprints.sep.16.sep.28.)

3 published preprints were added since September 16.

### [Newly added reference (Sep 25)](/page/updates/#changelog)

ter Ellen ter BM, Dinesh Kumar N, et int., and Smit JM. [â€œResveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.â€](/search/?article=Ellen%20ter20)Â  _bioRxiv_,Â  2020.Â  [doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).

### Database entries (Sep 24)
Pereda R, GonzÃ¡lez D, et int., and DomÃ­nguez RE. [â€œTherapeutic Effectiveness of Interferon-Î±2b Against COVID-19: The Cuban Experience.â€](/search/?article=Pereda20)Â _Journal of Interferon & Cytokine Research_,Â 2020.Â [doi.org/10.1089/jir.2020.0124](https://doi.org/10.1089/jir.2020.0124).Â \[[PubMed32960147](https://www.ncbi.nlm.nih.gov/pubmed/32960147/)\]

### [Clinical Trials (Sep 24)](/page/updates/#clinical.trials)
[10 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-09-04)

### [New [New spike structure (Sep 24)](/page/updates/#new.spike .structure (S.sep .24)](/page/updates/#features.)
We added a figure [Naturally occurring spike RBD variants and mAb escape mutations](/page/spike-structures/#fig10).

### [New table added (Sep 24)](/page/updates/#featuresnew.table.added.sep.24.)
We added a [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/) and data for six monoclonal antibodies.

### Database entries (Sep 23)[Newly added reference (Sep 23)](/page/updates/#changelog)

Cao L, Goreshnik I, et int., and Baker D. [â€œDe novo design of picomolar SARS-CoV-2 miniprotein inhibitors.â€](/search/?article=Cao20e)Â  _Science_,Â  2020.Â  [doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909).Â \[ [PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]

### [Interface update (Sep 22)](/page/updates/#featuresinterface.update.sep.22.)
We now support downloading CSV/Excel files for tables.

### [Editorial (Sep 21)](/page/updates/#papers)

Shafer R. â€œA SARS-CoVa.sars-cov-2 .antiviral .therapy score cardâ€ _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

### [Preprints => Peer-Reviewed Publications (Sep 16)](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added.

